ClinicalTrials.gg
CompletedNCT06366698IDAUpdated Nov 9, 2026

Intravenous Iron Versus Oral Iron for the Treatment of Iron Deficiency Anemia

A Phase 3 interventional study of Venofer 200 MG Per 10 ML Injection and Ferrous sulfate in Iron Deficiency Anemia of Pregnancy, sponsored by Arrowhead Regional Medical Center. Completed at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Arrowhead Regional Medical Center · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 2 months ago, and no results have been posted to the registry.
  • Registered 4 months after the study started (first participant enrolled Nov 2023, registered Apr 2024).
Updated Nov 9, 2026Now CompletedStudy documents posted+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
518
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies testing iron sucrose in Anemia — 1 open to participants now, 1 under way, none of them phase 3. iron sucrose · Anemia.

Enrollment
Largest of 29
518 · median 80
Started
2023
with 1 other
Phase 3
9 of 29
none open now
Registered
27th of 29
by date
Lead sponsor
1 of 29
Arrowhead Regional Medical Center

Among the 29 studies testing iron sucrose in Anemia, this one has the largest enrollment, is one of 2 that started in 2023, is one of 9 in phase 3, and was the 27th registered.

Anemia

1,812 studies on the registry are indexed under Anemia; 212 are open to participants now.

Browse Anemia studies →

Open to participants now

1 of the 29 studies testing iron sucrose in Anemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About iron sucrose

iron sucrose: first FDA approval 2000 (VENOFER). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 117 Anemia studies recruiting now, 66 (56%) set no upper age limit and 33 (28%) stop at 75 or younger; 32 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing iron sucrose in Anemia, or all of them as a file.
02

Study summary

This study aims to assess whether administering intravenous iron early in pregnancy, compared to standard oral iron treatment, can enhance hemoglobin levels before delivery and reduce the need for blood transfusions in patients with iron deficiency anemia. Patients diagnosed with iron deficiency anemia were randomly assigned to receive either oral or intravenous iron. Before treatment initiation, patients completed a symptom questionnaire baseline hemoglobin, and ferritin levels were measured. Follow-up visits occurred four weeks later and at 24 to 28 weeks gestation, involving reassessment of symptoms, laboratory testing, and monitoring of treatment adherence. Final hemoglobin levels were determined before delivery, and data on the need for blood transfusion at delivery were recorded.

Read the detailed description

Iron deficiency anemia is a prevalent health concern affecting approximately a quarter of the global population. In specific high-risk subgroups such as pregnancy, the occurrence of anemia is even higher. This condition is associated with adverse outcomes such as increased risks of blood transfusion, longer hospital stays, slower recovery, and depression, along with pregnancy risks such as preterm birth and low birth weight. Furthermore, infants born to iron-deficient mothers are at risk for delayed childhood growth and cognitive development. Preoperative optimization is crucial for improving clinical outcomes, as iron deficiency anemia accounts for over 80% of anemia cases in these patients.

Traditionally, oral (PO) iron supplementation has been the standard approach recommended by the American College of Obstetrics and Gynecology (ACOG) for preventing and addressing iron deficiency due to its simplicity and cost-effectiveness. However, it is marred by poor adherence to therapy and a high incidence of gastrointestinal side effects. While numerous publications have documented the safety and efficacy of intravenous (IV) iron, its utilization remains limited. Currently, IV iron is primarily reserved for patients who exhibit intolerance or an inadequate response to oral therapy. At our institution, we have taken proactive steps by administering IV iron infusions to many of our patients at an earlier gestational age, given the high rate of non-compliance with oral iron therapy. Our hypothesis proposes that individuals with iron deficiency anemia, defined as a serum ferritin level of less than 30 ng/mL (with 92% sensitivity and 98% specificity compared to hemoglobin (Hgb) levels), who receive IV iron infusions, will achieve higher Hgb levels upon admission and experience reduced rates of blood transfusions.

This study aims to assess the impact of IV iron infusions on pregnant patients with iron deficiency anemia. We hope that implementing this study will help improve overall population health. We hypothesize that individuals with iron deficiency anemia who receive IV iron infusions will attain higher Hgb levels at the time of admission and experience reduced rates of blood transfusions at the time of delivery.

After obtaining the patient's consent, they will be allocated into either of the two treatment options. All odd numbers will be in the oral iron group and even numbers enrolled into the IV iron group. We intend to administer Ferrous sulfate 325 mg orally every other day on an empty stomach with lemon/orange water, as numerous randomized control trials have demonstrated that increasing the iron dose does not lead to improved efficacy. Venofer 200 mg will be given every other day until the patient reaches their calculated iron deficit. The dose of IV iron will be calculated according to the Ganzoni formula: total iron dose (mg) = body weight (kg) x (target Hgb - baseline Hgb (g/dL)) × 0.24 + 500 mg. Our target Hgb will be 11.0 g/dL.

Patients will be given a symptom questionnaire at the time of enrollment to fill out. We will analyze the patient's ferritin, iron, total iron binding capacity (TIBC), Hgb level, mean corpuscular volume (MCV), and Hgb electrophoresis, which are routinely obtained on the first visit with prenatal labs. Four weeks after initiating treatment, patients will fill out a symptom and side effect questionnaire, and if on PO iron, their compliance will be assessed. Complete blood count (CBC) and iron studies will be repeated at that time. Other patient information such as admission CBC, post-delivery CBC, height, weight, body mass index (BMI), age, parity, gestational age at delivery, quantitative blood loss, route of delivery, need for blood transfusion, number of IV iron infusions, fetal birth weight, and antepartum/intrapartum/postpartum complications such as diabetes, preeclampsia/eclampsia, chorioamnionitis, and hemorrhage, etc., neonatal intensive care unit (NICU) admission as well as Edinburgh depression screening results, will be obtained from medical records. This information will be used for secondary outcomes analysis and to ensure there are no confounding factors. Statistical comparisons between groups will be performed using the two-way T-test followed by Tukey's test, or post hoc Student-Newman-Keuls tests. A P \< .05 will be considered a statistically significant difference among groups.

03

Conditions studied

  • Iron Deficiency Anemia of Pregnancy

Keywords

  • Anemia
  • Iron deficiency
  • Pregnancy
  • Intravenous iron
04

Who can participate

The criteria were revised on the registry on Nov 9, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > 18 years of age
  • Ferritin level \< 30 ng/mL
  • Single gestation
  • 14 0/7 to 34 6/7 weeks of gestation
  • Plan to deliver at Arrowhead Regional Medical Center (ARMC)

Exclusion criteria

Exclusion Criteria:

  • Maternal age \< 18 years of age
  • \< 7
  • Incarcerated patients
  • Multifetal gestation
  • Acute liver/kidney disease
  • Active infections
  • Known hematological
  • Other causes of anemia such as alpha/beta thalassemia, sickle cell disease, Folate/B12 deficiency, and anemia of chronic diseases
  • Known to IV iron
  • Severe symptoms of anemia requiring blood transfusion
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
518 participants (actual)

Study arms

  • Active comparator
    Intravenous iron

    Venofer 200 mg will be given every other day until the patient reaches their calculated in deficit dose. The does of IV iron will be calculated according to the Ganzoni formula: total iron dose (mg) = body weight (kg) x (target Hgb - baseline Hgb (g/dL)) × 0.24 + 500 mg.14 Our target Hgb will be 11.0 g/dL. The determination of the treatment duration and dosage will be based on the calculation of the iron deficit.

    Drug: Venofer 200 MG Per 10 ML Injection

  • Placebo comparator
    Oral iron

    Ferrous sulfate 325 mg orally every other day on an empty stomach with lemon/orange water until delivery.

    Drug: Ferrous sulfate

Interventions

  • DrugIron sucroseStudies of Iron sucroseIron sucrose pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    200 mg IV every 2 days until the targeted dose

    Also known as: Iron sucrose

  • DrugFerrous sulfate

    Take 1 tablet every other day with lemon/orange juice

06

What researchers measure

Primary outcomes

  1. Hemoglobin difference

    Change in hemoglobin level after intervention, larger difference mean more improvement in Hgb

    Time frame: Hemoglobin level obtained prior to treatment and then 4 weeks later

  2. Ferritin difference

    Change in ferritin level after intervention, larger difference mean more improvement in ferritin level

    Time frame: Ferritin level obtained prior to treatment and then 4 weeks later

Secondary outcomes

  1. Preterm delivery

    Comparing hemoglobin levels to gestational age at delivery

    Time frame: At the time of delivery

  2. Depression

    Edinburgh postnatal depression scale at first prenatal visit and postpartum. 10 questions with total score between 0-30. Higher score indicated increase risk for depression.

    Time frame: Duration of the pregnancy (up to 40 weeks) and up to 2 months postpartum

  3. Birthweight

    Comparing birthweight to hemoglobin levels at time of admission

    Time frame: At time of delivery

  4. Pre-delivery Hemoglobin

    Comparing pre-delivery hemoglobin levels

    Time frame: Obtained at time of delivery

  5. Symptoms

    Comparing number of anemia symptoms before and after treatment. There are 11 anemia symptoms on the questionnaire. Using a Likert scale from 0 (no symptoms) to 5 (severe symptoms) patient mark each one. The score is totaled up and can range from 0-55.

    Time frame: 4 weeks

  6. Rates of blood transfusion

    Comparing rates of blood transfusion at time of delivery between the 2 groups. The number of units transfused will be collected and compared among the groups

    Time frame: At time of delivery until 6 weeks postpartum

  7. Persistent anemia

    Comparing the number of patients with Hgb \< 10.5 after intervention

    Time frame: 4 weeks

  8. Treatment adherence

    Treatment adherence was assessed differently according to the assigned treatment group. In the oral iron group, adherence was evaluated using patient-reported responses to a follow-up survey regarding compliance with the prescribed alternate-day ferrous sulfate regimen. In the IV iron group, adherence was determined by reviewing infusion records to assess whether participants received the prescribed number of iron sucrose infusions based on their calculated iron deficit.

    Time frame: 4 weeks

  9. Adverse effects

    Medication-related adverse effects were assessed using a patient-reported survey. Participants were asked about symptoms or side effects experienced during treatment.

    Time frame: 4 weeks

  10. Blood loss

    Estimated maternal blood loss (mL) at the time of delivery, as documented in the medical record.

    Time frame: At the time of delivery until 5 days postpartum

  11. . Mode of delivery

    Mode of delivery, categorized as vaginal delivery or cesarean delivery, as documented in the medical record.

    Time frame: At the time of delivery

  12. Apgar scores

    Neonatal Apgar scores at 1 and 5 minutes after birth, as documented in the medical record. Range 0 to 10

    Time frame: At time of delivery, 1 and 5 minutes

  13. NICU admission

    Admission to the neonatal intensive care unit (NICU) following delivery, recorded as yes or no.

    Time frame: At the time of delivery until 5 days postpartum

  14. Neonatal hemoglobin

    Neonatal hemoglobin concentration (g/dL), as measured after birth and documented in the medical record.

    Time frame: At the time of delivery until 5 days postpartum

07

Study locations

1 site
08

References and documents

Publications

  • Froessler B, Palm P, Weber I, Hodyl NA, Singh R, Murphy EM. The Important Role for Intravenous Iron in Perioperative Patient Blood Management in Major Abdominal Surgery: A Randomized Controlled Trial. Ann Surg. 2016 Jul;264(1):41-6. doi: 10.1097/SLA.0000000000001646. PubMed 26817624 ↗
  • Anemia in Pregnancy: ACOG Practice Bulletin, Number 233. Obstet Gynecol. 2021 Aug 1;138(2):e55-e64. doi: 10.1097/AOG.0000000000004477. PubMed 34293770 ↗
  • Achebe MM, Gafter-Gvili A. How I treat anemia in pregnancy: iron, cobalamin, and folate. Blood. 2017 Feb 23;129(8):940-949. doi: 10.1182/blood-2016-08-672246. Epub 2016 Dec 29. PubMed 28034892 ↗
  • Tigga MP, Debbarma AP. A comparative study to evaluate oral iron and intravenous iron sucrose for treatment of anemia in pregnancy in a poor socioeconomic region of Northeast India. Tzu Chi Med J. 2019 Jul 24;32(3):258-261. doi: 10.4103/tcmj.tcmj_99_19. eCollection 2020 Jul-Sep. PubMed 32955516 ↗
  • Chua S, Gupta S, Curnow J, Gidaszewski B, Khajehei M, Diplock H. Intravenous iron vs blood for acute post-partum anaemia (IIBAPPA): a prospective randomised trial. BMC Pregnancy Childbirth. 2017 Dec 19;17(1):424. doi: 10.1186/s12884-017-1596-x. PubMed 29258541 ↗
  • Ng O, Keeler BD, Mishra A, Simpson JA, Neal K, Al-Hassi HO, Brookes MJ, Acheson AG. Iron therapy for preoperative anaemia. Cochrane Database Syst Rev. 2019 Dec 7;12(12):CD011588. doi: 10.1002/14651858.CD011588.pub3. PubMed 31811820 ↗
  • Nicholls G, Mehta R, McVeagh K, Egan M. The Effects of Intravenous Iron Infusion on Preoperative Hemoglobin Concentration in Iron Deficiency Anemia: Retrospective Observational Study. Interact J Med Res. 2022 Feb 3;11(1):e31082. doi: 10.2196/31082. PubMed 35113024 ↗
  • Lewkowitz AK, Stout MJ, Cooke E, Deoni SC, D'Sa V, Rouse DJ, Carter EB, Tuuli MG. Intravenous versus Oral Iron for Iron-Deficiency Anemia in Pregnancy (IVIDA): A Randomized Controlled Trial. Am J Perinatol. 2022 Jun;39(8):808-815. doi: 10.1055/s-0041-1740003. Epub 2021 Nov 28. PubMed 34839481 ↗
  • Wong L, Smith S, Gilstrop M, Derman R, Auerbach S, London N, Lenowitz S, Bahrain H, McClintock J, Auerbach M. Safety and efficacy of rapid (1,000 mg in 1 hr) intravenous iron dextran for treatment of maternal iron deficient anemia of pregnancy. Am J Hematol. 2016 Jun;91(6):590-3. doi: 10.1002/ajh.24361. Epub 2016 Apr 13. PubMed 26971581 ↗
  • Hansen R, Sommer VM, Pinborg A, Krebs L, Thomsen LL, Moos T, Holm C. Intravenous ferric derisomaltose versus oral iron for persistent iron deficient pregnant women: a randomised controlled trial. Arch Gynecol Obstet. 2023 Oct;308(4):1165-1173. doi: 10.1007/s00404-022-06768-x. Epub 2022 Sep 15. PubMed 36107229 ↗
  • Govindappagari S, Burwick RM. Treatment of Iron Deficiency Anemia in Pregnancy with Intravenous versus Oral Iron: Systematic Review and Meta-Analysis. Am J Perinatol. 2019 Mar;36(4):366-376. doi: 10.1055/s-0038-1668555. Epub 2018 Aug 19. PubMed 30121943 ↗
  • Stoffel NU, Zeder C, Brittenham GM, Moretti D, Zimmermann MB. Iron absorption from supplements is greater with alternate day than with consecutive day dosing in iron-deficient anemic women. Haematologica. 2020 May;105(5):1232-1239. doi: 10.3324/haematol.2019.220830. Epub 2019 Aug 14. PubMed 31413088 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Sep 2025, 21 months.

Of 50 non-industry phase 3 interventional studies under Anemia, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's 21 months is below that.

Counting every sponsor, half of 148 studies reached it within 30 months; a quarter within 17 and three quarters within 51.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Dec 2025 → Sep 2025 and completion Dec 2025 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2024
First posted
Apr 16, 2024
StartActual
Nov 21, 2023
Primary completionActual
Sep 12, 2025was Dec 2025
CompletionActual
Oct 30, 2026was Dec 2025
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 9, 2026
Primary completion
Dec 30, 2025→Sep 12, 2025 (actual)
Nov 9, 2026
Study completion
Dec 30, 2025→Oct 30, 2026 (actual)
Nov 9, 2026
Enrollment
900 (estimated)→518 (actual)
Nov 9, 2026
Eligibility
2 inclusion criteria edited, 1 added, 1 removed; 1 exclusion criterion edited, 1 added
What changed in the criteria
Inclusion criteria
  • EditedSingeSingle gestation
  • RemovedGestational age up to 36 weeks as iron therapy after this has shown to be not beneficial at time of delivery. We will still plan to treat patients > 36 weeks but not include them in the final analysis
  • Added14 0/7 to 34 6/7 weeks of gestation
  • EditedPlan to deliverydeliver at Arrowhead Regional Medical Center (ARMC)
Exclusion criteria
  • AddedHgb < 7
  • EditedKnown hypersensitivity withto IV iron
Nov 9, 2026
Primary outcomes
3 removed
What changed in the outcomes
  • RemovedDelivery HemoglobinTime frame: Obtained at time of delivery
  • RemovedRates of blood transfusionTime frame: At time of delivery until 6 weeks postpartum
  • RemovedSymptomsTime frame: 4 weeks
Nov 9, 2026
Documents
Nov 9, 2026
Secondary outcomes
11 added
What changed in the outcomes
  • AddedPre-delivery HemoglobinTime frame: Obtained at time of delivery
  • AddedSymptomsTime frame: 4 weeks
  • AddedRates of blood transfusionTime frame: At time of delivery until 6 weeks postpartum
  • AddedPersistent anemiaTime frame: 4 weeks
  • AddedTreatment adherenceTime frame: 4 weeks
  • AddedAdverse effectsTime frame: 4 weeks
  • AddedBlood lossTime frame: At the time of delivery until 5 days postpartum
  • Added. Mode of deliveryTime frame: At the time of delivery
  • AddedApgar scoresTime frame: At time of delivery, 1 and 5 minutes
  • AddedNICU admissionTime frame: At the time of delivery until 5 days postpartum
  • AddedNeonatal hemoglobinTime frame: At the time of delivery until 5 days postpartum
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Recruiting→Completed
    Documents Informed consent form ↗ updated
    Primary completion Dec 30, 2025→Sep 12, 2025 (now actual)
    Study completion Dec 30, 2025→Oct 30, 2026 (now actual)
    Enrollment 900 (estimated)→518 (actual)
    Eligibility 2 inclusion criteria edited, 1 added, 1 removed; 1 exclusion criterion edited, 1 added
    What changed in the criteria
    Inclusion criteria
    • EditedSingeSingle gestation
    • RemovedGestational age up to 36 weeks as iron therapy after this has shown to be not beneficial at time of delivery. We will still plan to treat patients > 36 weeks but not include them in the final analysis
    • Added14 0/7 to 34 6/7 weeks of gestation
    • EditedPlan to deliverydeliver at Arrowhead Regional Medical Center (ARMC)
    Exclusion criteria
    • AddedHgb < 7
    • EditedKnown hypersensitivity withto IV iron
    Primary outcomes 3 removed
    What changed in the outcomes
    • RemovedDelivery HemoglobinTime frame: Obtained at time of delivery
    • RemovedRates of blood transfusionTime frame: At time of delivery until 6 weeks postpartum
    • RemovedSymptomsTime frame: 4 weeks
    Secondary outcomes 11 added
    What changed in the outcomes
    • AddedPre-delivery HemoglobinTime frame: Obtained at time of delivery
    • AddedSymptomsTime frame: 4 weeks
    • AddedRates of blood transfusionTime frame: At time of delivery until 6 weeks postpartum
    • AddedPersistent anemiaTime frame: 4 weeks
    • AddedTreatment adherenceTime frame: 4 weeks
    • AddedAdverse effectsTime frame: 4 weeks
    • AddedBlood lossTime frame: At the time of delivery until 5 days postpartum
    • Added. Mode of deliveryTime frame: At the time of delivery
    • AddedApgar scoresTime frame: At time of delivery, 1 and 5 minutes
    • AddedNICU admissionTime frame: At the time of delivery until 5 days postpartum
    • AddedNeonatal hemoglobinTime frame: At the time of delivery until 5 days postpartum
    + 6 other changes: identifiers, verification date, description, design details, site details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06366698
Lead sponsor
Arrowhead Regional Medical Center
Responsible party
Sponsor
First posted
Apr 16, 2024
Start date
Nov 21, 2023
Primary completion
Sep 12, 2025
Completion
Oct 30, 2026
Last update
Nov 9, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iron sucrose

Start the discussion